SWOG clinical trial number
CTSU/R0415

A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer

Closed
Phase
Abbreviated Title
Local Prostate
Activated
07/01/2006
Closed
11/06/2009
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Radiation Therapy

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.

Publication Information Expand/Collapse

2019

Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415

M Thor;J Deasy;R Paulus;W Lee;M Amin;D Bruner;D Low;A Shah;S Malone;J Michalski;I Dayes;S Seaward;E Gore;M Albert;T Pisansky;S Faria;Y Chen;B Koontz;G Swanson;S Pugh;H Sandler Radiotherapy and Oncology Jun;135:19-24; doi: 10.1016/j.radonc.2019.02.014. Epub 2019 Mar 5.

PMid: PMID31015166 | PMC number: PMC6582638

Other Clinical Trials

SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase